title: Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations.
abstract: Han population is six times as likely as Kazak population to present with type 2 diabetes mellitus (T2DM) in China. We hypothesize that differential expression and CpG methylation of miR-375 may be an ethnic-related factor that influences the incidence of T2DM. The expression level of miR-375 was examined using real-time PCR on Kazak and Han T2DM plasma samples. Furthermore, the methylation levels of CpG sites of miR-375 promoter were determined by MassARRAY Spectrometry in these samples. The relative expression levels of plasma miR-375 in Kazak T2DM samples are 1, and the relative expression levels of plasma miR-375 in Han T2DM samples are 3. The mean level of miR-375 methylation, calculated from the methylation levels of the CpG sites, was 8.47% for the Kazak T2DM group and 10.38% for the Han T2DM group. Further, five CpG units showed a statistically significant difference between Kazak and Han T2DM samples, and, among them, four were hypomethylated and only one CpG unit showed hypermethylation in Kazak T2DM samples. These findings indicate that the expression levels of plasma miR-375 and its CpG methylation in the promoter region are ethnically different, which may contribute to the different incidence of diabetes observed in Kazak and Han populations.
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Xiangyun
authors.initials: X
authors.lastname: Chang
authors.affiliation: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Siyuan
authors.initials: S
authors.lastname: Li
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Yin
authors.affiliation: The Central Laboratory, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Chen
authors.affiliation: Departments of Endocrinology and Metabolism, First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang 832002, China.
authors.forename: Kan
authors.initials: K
authors.lastname: Sun
mesh_terms: D044466:Asian People; D002681:China / Q000453:epidemiology; D018899:CpG Islands; D019175:DNA Methylation; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000208:ethnology / Q000378:metabolism* / Q000503:physiopathology; D018450:Disease Progression; D044127:Epigenesis, Genetic; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D006785:Hospitals, University; D006801:Humans; D015994:Incidence; D035683:MicroRNAs / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D015995:Prevalence; D011401:Promoter Regions, Genetic; D011446:Prospective Studies; D015203:Reproducibility of Results; D012307:Risk Factors
chemical_list: C540933:MIRN375 microRNA, human; D035683:MicroRNAs
references.citation: Cancer Res. 2010 Nov 15;70(22):9175-84
references.pmid: 20978187
references.citation: Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5813-8
references.pmid: 19289822
references.citation: Nature. 2004 Nov 11;432(7014):226-30
references.pmid: 15538371
references.citation: Cell Cycle. 2007 May 2;6(9):1001-5
references.pmid: 17457051
references.citation: Cell Res. 2010 Jul;20(7):784-93
references.pmid: 20548334
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Cancer Res. 2010 Mar 15;70(6):2339-49
references.pmid: 20215506
references.citation: Cancer Res. 2008 Dec 15;68(24):10257-66
references.pmid: 19074894
references.citation: Cardiovasc Toxicol. 2008 Dec;8(4):155-9
references.pmid: 18777166
references.citation: Nature. 2004 Sep 16;431(7006):350-5
references.pmid: 15372042
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references.pmid: 18663219
references.citation: Mol Med Rep. 2014 Mar;9(3):967-72
references.pmid: 24366165
references.citation: Mol Cancer Res. 2011 Jun;9(6):791-800
references.pmid: 21593139
references.citation: Oncogene. 2010 Jul 29;29(30):4297-306
references.pmid: 20514023